Cofactor Genomics
Cofactor Genomics develops RNA-based predictive diagnostics that help match cancer patients with effective immunotherapy treatments. Its OncoPrism tests analyze FFPE tumor specimens to generate a Response Score predicting treatment likelihood, with validated tests for head and neck squamous cell carcinoma and non-small cell lung cancer. The company operates a CAP/CLIA certified laboratory and has received Medicare approval for its immunotherapy test.
- Healthcare Technology
- Biotechnology
- Data & Analytics
- Artificial Intelligence
Funding
Funding not disclosed
Founders
Founder details are not available yet.
Product
Problem
Clinicians lack accurate tools to predict which cancer patients will respond to immunotherapy, leading to ineffective treatments, delayed care, and poor outcomes. Single-analyte biomarkers have limited predictive value, and better diagnostics are needed to guide treatment decisions ahead of therapy.
Solution
Cofactor Genomics builds next-generation predictive diagnostics that use RNA to match cancer patients with effective treatments. The company's ImmunoPrism platform profiles each patient's immune response using RNA extracted from FFPE solid tumor specimens, then applies machine learning-based Predictive Immune Modeling to identify the most important immune signals. These multidimensional biomarkers are deployed as OncoPrism clinical tests, which generate a Response Score predicting the likelihood a patient will respond to immunotherapy. The tests are run in a CAP/CLIA laboratory as laboratory developed tests, and results can be used in clinical decision making.
Target Audience
Primary customers are medical oncologists, pathologists, and clinical researchers pursuing immune-oncology indications, as well as biopharmaceutical companies seeking to identify treatment-responsive patient subsets in clinical trials.
Features
- OncoPrism-HNSCC and OncoPrism-NSCLC clinical tests validated for predicting immunotherapy response in head and neck squamous cell carcinoma and non-small cell lung cancer
- ImmunoPrism immune profiling platform analyzes RNA from FFPE solid tumor specimens to quantify key immune signals including cells and transcripts
- Machine learning-based Predictive Immune Modeling combines multiple analytes into a single multidimensional biomarker with high predictive value
- Proprietary database of immune HEMs (highly expressed markers) built from analysis of 25,000 genes to identify the 40 that matter for response prediction
- CAP/CLIA certified laboratory offering laboratory developed tests for clinical use, with Research Use Only products also available